[Efficacy and safety of recombinant tissue plasminogen activator in thrombolytic therapy of vena caval thromboembolism].

Abstract

OBJECTIVE:

To explore the efficacy and safety of recombinant tissue plasminogen activator (rt-PA) in thrombolytic therapy of vena caval thromboembolism.

METHODS:

Ninety patients diagnosed of vena caval thromboembolism by ultrasound or angiography of inferior vena cava were randomly assigned into 2 groups. rt-PA and parental anticoagulant were given to the patients in the treatment group while those in the control group received only parental anticoagulation. D-dimer, fibrinogen and fibrinogen degradation product were analyzed after 2-week treatment. All subjects were closely monitored for the occurrence of severe complications.

RESULTS:

The changes from baseline in the above laboratory parameters in the treatment group were significantly greater than those of the control group (P < 0.05). No severe complications occurred in either group.

CONCLUSION:

rt-PA is both safe and effective for the thrombolytic therapy of vena caval thromboembolism.

• Authors: Wei Jia, Jian-long Liu, Xuan Tian, Peng Jiang
• Journal: Zhonghua yi xue za zhi (Zhonghua Yi Xue Za Zhi) Vol. 93 Issue 47 Pg. 3783-5 (Dec 17 2013) ISSN: 0376-2491 [Print] China
• PMID: 24548399 (Publication Type: English Abstract, Journal Article, Randomized Controlled Trial)

Chemical References

• Recombinant Proteins
• Tissue Plasminogen Activator

Topics

• Adult
• Female
• Humans
• Male
• Middle Aged
• Recombinant Proteins (therapeutic use)
• Thrombolytic Therapy
• Tissue Plasminogen Activator (therapeutic use)
• Vena Cava, Inferior (pathology)
• Venous Thrombosis (drug therapy)
• Young Adult